Product Comparison

Comparison Options

• Print
• Email
• Export Compare

	No Image
McKesson #	819039	952614	544446	357993
Description	CUP,RLLD RIM PPR CONE 5OZ	Gardasil® 9 Human Papillomavirus 9-Valent Vaccine, Recombinant, Preservative Free 20 mcg - 60 mcg / 0.5 mL Injection 0.5 mL	RotaTeq® Rotavirus Vaccine, Live, Oral Pentavalent Solution 2 mL	PedvaxHIB® Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) 7.5 mcg / 0.5 mL Injection 0.5 mL
Manufacturer #	KCI-45KR	00006412102	00006404741	00006489700
Brand		Gardasil® 9	RotaTeq®	PedvaxHIB®
Manufacturer	ESSENDANT CO/UNITED STATIONERS	Merck	Merck	Merck
Invoice	CUP,RLLD RIM PPR CONE 5OZ	GARDASIL 9 HPV VACC, SYR 0.5ML(10/BX)	ROTATEQ VAC, SUSP 2ML LIVE PENTAV (10/PK)	PEDVAXHIB, VL 0.5ML (10/BX)
	Log In to Order	Log In to Order	Log In to Order	Log In to Order
Comparison
Application		Human Papillomavirus Vaccine (HPV)	Rotavirus Vaccine	Haemophilus Influenzae Type b Vaccine (Hib)
Container Type		Prefilled Syringe	Single-Dose Tube	Single-Dose Vial
Country of Origin	Unknown	Austria	United States	United States
Dosage Form		Injection	Solution	Injection
Generic Drug Code		37568	26500	99344
Generic Drug Name		Human Papillomavirus 9-Valent Vaccine, Recombinant, Preservative Free	Rotavirus Vaccine, Live, Oral Pentavalent	Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)
NDC Number		00006412102	00006404741	00006489700
Product Dating		McKesson Acceptable Dating: we will ship >= 180 days	McKesson Acceptable Dating: we will ship >= 90 days	McKesson Acceptable Dating: we will ship >= 180 days
Storage Requirements		Requires Refrigeration	Requires Refrigeration	Requires Refrigeration
Strength		20 mcg - 60 mcg / 0.5 mL		7.5 mcg / 0.5 mL
Type		Intramuscular	Oral	Intramuscular
UNSPSC Code		51201649	51201618	51201627
User		Indicated for People 9 to 45 Years of Age	Indicated for People 6 to 32 Weeks of Age	Indicated for People 2 to 71 Months of Age
Volume		0.5 mL	2 mL	0.5 mL
Features and Benefits		GARDASIL 9 is a non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 Each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein Administer GARDASIL 9 intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58	The vaccination series consists of three ready-to-use liquid doses of RotaTeq* administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4 to 10 week intervals 10 individually pouched single dose tubes Each dose is supplied in a container consisting of a squeezable plastic dosing tube with a twist-off cap, allowing for direct oral administration	Each 0.5 mL dose of Liquid PedvaxHIB is a sterile product formulated to contain: 7.5 mcg of Haemophilus b PRP, 125 mcg of Neisseria meningitidis OMPC and 225 mcg of aluminum as amorphous aluminum hydroxyphosphate sulfate (previously referred to as aluminum hydroxide), in 0.9% sodium chloride, but does not contain lactose or thimerosal